Note 5 - Related Party Transactions (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
	Mar. 28, 2018	Mar. 12, 2018	Aug. 21, 2017	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Nov. 26, 2019	Mar. 31, 2019	Apr. 16, 2018	Apr. 01, 2018	Mar. 31, 2017
Stock Issued During Period, Shares, New Issues	60,964
Shares Issued, Price Per Share	$ 22.70
Revenue from Contract with Customer, Including Assessed Tax					$ 12,160,000	$ 9,003,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(10,099,000)	(40,940,000)
Income (Loss) from Equity Method Investments, Total					(15,000)
Assets, Current, Total				$ 9,861,000	9,861,000	8,626,000
Liabilities, Current, Total				6,685,000	6,685,000	6,365,000
Amortization of Debt Discount (Premium)					2,349,000	1,174,000
Revenue from Related Parties					887,000	669,000
Gross Profit, Total					5,696,000	$ 2,193,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total								$ 1,513,000		$ 7,200,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price						$ 1.80			$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000	10,000,000						$ 10,000,000
Proceeds from Long-term Lines of Credit					8,713,000	$ 7,200,000
Line of Credit Facility, Remaining Borrowing Capacity				$ 1,287,000	$ 1,287,000
Debt Instrument, Interest Rate, Stated Percentage				22.00%	22.00%
Amortization of Debt Discount (Premium)					$ 2,344,000	1,174,000
Interest Payable				$ 1,869,000	1,869,000	1,513,000
Boyalife W.S.N. [Member]
Distributor Agreement Term			3 years
Distributor Agreement, Renewal Term			2 years
Revenue from Related Parties					794,000	665,000
Accounts Receivable, Related Parties				20,000	20,000	0
IncoCell [Member]
Revenue from Related Parties					83,000	14,000
Accounts Receivable, Related Parties				83,000	$ 83,000	$ 14,000
Contract Development Revenue, Term		10 years
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock				$ 3,000,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues				600,000
Shares Issued, Price Per Share				$ 5	$ 5
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage				18.87%	18.87%		20.00%
Joint Venture Purchase, Percent of Company's Cost							115.00%
Line of Credit Facility, Maximum Borrowing Capacity							$ 1,000,000
Equity Method Investment, Aggregate Cost							$ 28,000
Revenue from Contract with Customer, Including Assessed Tax					$ 0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(78,000)
Income (Loss) from Equity Method Investments, Total					(15,000)
Assets, Current, Total				$ 3,000,000	3,000,000
Assets, Noncurrent, Total				8,000	8,000
Liabilities, Current, Total				14,000	14,000
Liabilities, Noncurrent, Total				$ 0	0
Gross Profit, Total					$ 0
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.47%	75.47%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage				5.66%	5.66%